Show simple item record

dc.contributor.authorKankaanpää, J
dc.contributor.authorSämpi, M
dc.contributor.authorBloigu, R
dc.contributor.authorWang, C
dc.contributor.authorAkhi, R
dc.contributor.authorKesäniemi, YA
dc.contributor.authorRemes, AM
dc.contributor.authorUkkola, O
dc.contributor.authorHörkkö, S
dc.date.accessioned2018-04-10T11:07:20Z
dc.date.available2018-04-10T11:07:20Z
dc.date.issued2018
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/6284
dc.description.abstractBackground and aims Antibodies to phosphocholine and oxidized LDL (oxLDL) are proposed to modify progression of atherosclerosis. We investigated the prognostic value of antibodies to phosphocholine (PCho), Streptococcus pneumoniae cell wall polysaccharide (CWPS) and oxLDL in defining long-term CVD survival. Methods CVD incidence was followed for 18 years and analyzed with baseline plasma IgM, IgG and IgA antibody levels to PCho, CWPS and oxLDL in 1044 subjects of Oulu Project Elucidating Risk of Atherosclerosis study (OPERA). Results During the follow-up period, 195 subjects (18.7%) had a CVD event. Cox model with ACC/AHA CVD adjustments (ASCVD) showed that IgA levels to PCho and IgA to CWPS were statistically significant factors predicting CVD risk. IgM and IgG antibodies to PCho, CWPS and oxLDL had no effect on CVD risk after adjusting for other risk factors. Net reclassification improvement (categories: 17-year risk <15%, 15–30%, >30%), was 0.06 (−0.001–0.12, p < 0.054), and IDI was 0.0124 (0.0036–0.0211, p < 0.006) with IgA-PCho added to the ASCVD risk model. Seventeen (9.4%) study subjects with CVD events were correctly reclassified into higher risk category while 9 (5.0%) subjects were classified into lower risk category. Among the non-cases, 58 (8.7%) subjects were correctly reclassified into lower risk, and 46 (5.9%) were reclassified into higher risk category. Conclusions Plasma IgA antibodies to PCho and Streptococcus pneumoniae CWPS are significant predictors of long-term CVD risk. Additional studies on the role of IgA antibodies in atherogenesis and CVD are warranted.
dc.language.isoEN
dc.publisherElsevier BV
dc.relation.ispartofseriesATHEROSCLEROSIS
dc.relation.urihttp://dx.doi.org/10.1016/j.atherosclerosis.2017.12.010
dc.rightsCC BY-NC-ND https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectphosphocholine
dc.subjectStreptococcus pneumoniae
dc.subjectantibody
dc.subjectcardiovascular disease
dc.subjectbiomarker
dc.titleIgA antibodies to phosphocholine associate with long-term cardiovascular disease risk
dc.description.versionfinal draft
dc.contributor.departmentSchool of Medicine / Clinical Medicine
uef.solecris.id51596444en
dc.type.publicationTieteelliset aikakauslehtiartikkelit
dc.rights.accessrights© Elsevier B.V.
dc.relation.doi10.1016/j.atherosclerosis.2017.12.010
dc.description.reviewstatuspeerReviewed
dc.format.pagerange294-300
dc.relation.issn0021-9150
dc.relation.volume269
dc.rights.accesslevelopenAccess
dc.type.okmA1
uef.solecris.openaccessEi


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record